What is an “expected” or “labeled” adverse reaction versus an “unexpected” or “unlabeled” adverse event or experience? Unfortunately, present guidelines that assist with this assessment are not well defined, thus creating ambiguity in their interpretation and application. In an attempt to establish a definitive framework for assessing “expectedness” or “labeledness,” formalized guidelines for interpreting and formatting safety information have been drafted. Although this article is written from a United States regulatory perspective, many of the guidelines can be applied globally.
Expedited Safety Reporting Requirements for Human Drug and Biological Products [Docket No. 93N-0181]Fed Register. 1997; Vol. 62, No. 194, p. 52237 at 52240.
2.
PhillipsGCastleW.Standardizing “expectedness” and “seriousness” for adverse experience case reporting. Drug Inf J.1996(1);30:73–81.
3.
21CFR310.305(b).
4.
21CFR314.80(a).
5.
21CFR600.80(a).
6.
21CFR201.57(g).
7.
21CFR312.32(a).
8.
Guideline for Postmarketing Reporting of Adverse Experiences. [Docket No. 85D-0249]. Rockville, MD: Food and Drug Administration, Center for Drug Evaluation and Research; March 1992.
9.
Guideline for Adverse Experience Reporting for Licensed Biological Products. [Docket No. 85D-0505]. Rockville, MD: Food and Drug Administration, Center for Biologics Evaluation and Research; October 15, 1993.
10.
“Adverse Drug Reaction Reporting,”Food & Drug Administration Division of Epidemiology and Surveillance, Drug Information Association Workshop. May 6, 1988.
11.
International Conference on Harmonisation.Guideline on Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs [E2C]; Availability; Notice. Fed Register. 1997; Vol. 62, No. 96, p. 17471 at 27472.
12.
Guidelines for Preparing Core Clinical-Safety Information on Drugs. Report of CIOMS Working Groups III and V. Geneva, Switzerland: Council for International Organizations of Medical Sciences; 1999.
13.
International Conference on Harmonisation. Guideline on Clinical Safety Data Management; Notice [E2A]. Fed Register. 1995; Vol. 60, No. 40.
14.
NakaoMAAxelrodS.Numbers are better than words—Verbal expressions of frequency have no place in medicine. Am J Med.1983;74:1061–1065.
15.
Instructions For Completing FDA Form 3500A.MedWatch: The FDA Medical Products Reporting Program. 1993.
16.
21CFR201.56(d)(1)(2).
17.
21CFR201.57.
18.
21CFR201.57(g)(2).
19.
21CFR314.70(c)(2)(i)(ii).
20.
21CFR314.70(b)(3).
21.
International Conference on Harmonisation. Good Clinical Practice: Consolidated Guideline; Notice of Availability. Fed Register. 1997; Vol. 62, No. 90, p. 25692 at 25704.
22.
Expedited Safety Reporting Requirements for Human Drug and Biological Products [Docket No. 93N-0181] Fed Register. 1997; Vol. 62, No. 194, p. 52237 at 52245.
